Healthcare / Medical Instruments & SuppliesSwiss
$50.60
+0.50 (+1.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-7.1M · quality 39.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
70.3x
↑EV/EBITDA
33.1x
↑ROE
14.2%
↑Gross Margin
77.0%
↑Debt/Equity
1.15
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.4%
FCF CAGR
-17.6%
FCF margin
5.5%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $333.3M · net income $16.3M · FCF $18.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $333.3M | $333.3M | $361.3M | $320.0M | $277.0M |
| Net Income | $16.3M | $16.3M | $38.8M | $26.3M | $19.0M |
| EBITDA | $35.5M | $35.5M | $59.7M | $45.5M | $36.4M |
| EPS | 0.72 | 0.72 | 1.73 | 1.17 | 0.84 |
| Gross Margin | 77.0% | 77.0% | 73.6% | 75.2% | 72.4% |
| Operating Margin | 7.6% | 7.6% | 12.3% | 11.8% | 10.6% |
| Net Margin | 4.9% | 4.9% | 10.7% | 8.2% | 6.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.15 | 1.15 | 0.05 | 0.04 | 0.11 |
| Current Ratio | 1.31 | 1.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $18.2M | $18.2M | $-7.1M | $-26.6M | $32.6M |
| Returns | |||||
| ROE | 14.2% | 14.2% | 19.8% | 15.5% | 12.1% |
| Valuation | |||||
| P/E | 70.28 | 70.28 | 44.62 | 66.15 | 76.55 |
| EV/EBITDA | 33.08 | 33.08 | 28.36 | 36.48 | 37.13 |
| P/B | 9.94 | 9.94 | 8.85 | 10.28 | 9.19 |
| Growth & Yield | |||||
| Revenue Growth | -7.7% | -7.7% | 12.9% | 15.5% | — |
| EPS Growth | -58.4% | -58.4% | 47.9% | 39.3% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
84.1%
EPS terminal req.
$4.49
Spread vs growth
-142.4%
5Y implied EPS CAGR
49.8%
EPS terminal req.
$5.43
Spread vs growth
-108.2%
10Y implied EPS CAGR
28.4%
EPS terminal req.
$8.75
Spread vs growth
-86.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.0%
Start / end P/E
41.4x → 70.3x
EPS bridge
1.73 → 0.72
Residual
-40.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.